170 related articles for article (PubMed ID: 25997473)
1. Frequency of TERT Promoter Mutations in Prostate Cancer.
Stoehr R; Taubert H; Zinnall U; Giedl J; Gaisa NT; Burger M; Ruemmele P; Hurst CD; Knowles MA; Wullich B; Hartmann A
Pathobiology; 2015; 82(2):53-7. PubMed ID: 25997473
[TBL] [Abstract][Full Text] [Related]
2. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
[TBL] [Abstract][Full Text] [Related]
3. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
Cevik D; Yildiz G; Ozturk M
World J Gastroenterol; 2015 Jan; 21(1):311-7. PubMed ID: 25574106
[TBL] [Abstract][Full Text] [Related]
4. Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma.
Priemer DS; Wang M; Zhang S; Lopez-Beltran A; Kouba E; Montironi R; Davidson DD; MacLennan GT; Wang L; Osunkoya AO; Deng Y; Emerson RE; Cheng L
Eur Urol Focus; 2018 Dec; 4(6):880-888. PubMed ID: 28753872
[TBL] [Abstract][Full Text] [Related]
5. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis.
Nault JC; Calderaro J; Di Tommaso L; Balabaud C; Zafrani ES; Bioulac-Sage P; Roncalli M; Zucman-Rossi J
Hepatology; 2014 Dec; 60(6):1983-92. PubMed ID: 25123086
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions.
Koopmans AE; Ober K; Dubbink HJ; Paridaens D; Naus NC; Belunek S; Krist B; Post E; Zwarthoff EC; de Klein A; Verdijk RM;
Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):6024-30. PubMed ID: 25159205
[TBL] [Abstract][Full Text] [Related]
7. Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia.
Papathomas TG; Oudijk L; Zwarthoff EC; Post E; Duijkers FA; van Noesel MM; Hofland LJ; Pollard PJ; Maher ER; Restuccia DF; Feelders RA; Franssen GJ; Timmers HJ; Sleijfer S; de Herder WW; de Krijger RR; Dinjens WN; Korpershoek E
Endocr Relat Cancer; 2014 Aug; 21(4):653-61. PubMed ID: 24951106
[TBL] [Abstract][Full Text] [Related]
8. Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a genomic and molecular study.
Wu S; Huang P; Li C; Huang Y; Li X; Wang Y; Chen C; Lv Z; Tang A; Sun X; Lu J; Li W; Zhou J; Gui Y; Zhou F; Wang D; Cai Z
Eur Urol; 2014 Feb; 65(2):274-7. PubMed ID: 24215939
[TBL] [Abstract][Full Text] [Related]
9. Frequent TERT Promoter Mutations in Ocular Surface Squamous Neoplasia.
Scholz SL; Thomasen H; Reis H; Möller I; Darawsha R; Müller B; Dekowski D; Sucker A; Schilling B; Schadendorf D; Steuhl KP; Paschen A; Westekemper H; Meller D; Griewank KG
Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5854-61. PubMed ID: 26348634
[TBL] [Abstract][Full Text] [Related]
10. TERT promoter mutations in sinonasal malignant melanoma: a study of 49 cases.
Jangard M; Zebary A; Ragnarsson-Olding B; Hansson J
Melanoma Res; 2015 Jun; 25(3):185-8. PubMed ID: 25746036
[TBL] [Abstract][Full Text] [Related]
11. TERT promoter mutation is uncommon in acral lentiginous melanoma.
Liau JY; Tsai JH; Jeng YM; Chu CY; Kuo KT; Liang CW
J Cutan Pathol; 2014 Jun; 41(6):504-8. PubMed ID: 24588324
[TBL] [Abstract][Full Text] [Related]
12. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.
Arita H; Narita Y; Fukushima S; Tateishi K; Matsushita Y; Yoshida A; Miyakita Y; Ohno M; Collins VP; Kawahara N; Shibui S; Ichimura K
Acta Neuropathol; 2013 Aug; 126(2):267-76. PubMed ID: 23764841
[TBL] [Abstract][Full Text] [Related]
13. Frequency of TERT promoter mutations in primary tumors of the liver.
Quaas A; Oldopp T; Tharun L; Klingenfeld C; Krech T; Sauter G; Grob TJ
Virchows Arch; 2014 Dec; 465(6):673-7. PubMed ID: 25267585
[TBL] [Abstract][Full Text] [Related]
14. Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder.
Vail E; Zheng X; Zhou M; Yang X; Fallon JT; Epstein JI; Zhong M
Ann Diagn Pathol; 2015 Oct; 19(5):301-5. PubMed ID: 26239299
[TBL] [Abstract][Full Text] [Related]
15. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
[TBL] [Abstract][Full Text] [Related]
16. Telomerase reverse transcriptase promoter mutations in cancers derived from multiple organ sites among middle eastern population.
Siraj AK; Bu R; Iqbal K; Parvathareddy SK; Siraj N; Siraj S; Diaz MRF; Rala DR; Benito AD; Sabido MA; Al-Rasheed M; Al-Obaisi KAS; Al-Haqawi W; Victoria IG; Al Balawy W; Abedalthagafi M; Wakil SM; Ajarim D; Mohammed S; Alhussain T; Tulbah A; Al-Badawi IA; Al-Dayel F; Al-Kuraya KS
Genomics; 2020 Mar; 112(2):1746-1753. PubMed ID: 31669704
[TBL] [Abstract][Full Text] [Related]
17. Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change.
Cheng L; Davidson DD; Wang M; Lopez-Beltran A; Montironi R; Wang L; Tan PH; MacLennan GT; Williamson SR; Zhang S
Histopathology; 2016 Jul; 69(1):107-13. PubMed ID: 26679899
[TBL] [Abstract][Full Text] [Related]
18. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
Liu T; Wang N; Cao J; Sofiadis A; Dinets A; Zedenius J; Larsson C; Xu D
Oncogene; 2014 Oct; 33(42):4978-84. PubMed ID: 24141777
[TBL] [Abstract][Full Text] [Related]
19. TERT promoter hotspot mutations in breast cancer.
Shimoi T; Yoshida M; Kitamura Y; Yoshino T; Kawachi A; Shimomura A; Noguchi E; Yunokawa M; Yonemori K; Shimizu C; Kinoshita T; Ichimura K; Fukuda T; Fujiwara Y; Tamura K
Breast Cancer; 2018 May; 25(3):292-296. PubMed ID: 29222734
[TBL] [Abstract][Full Text] [Related]
20. TERT promoter mutations in periocular carcinomas: implications of ultraviolet light in pathogenesis.
Lin SY; Liao SL; Hong JB; Chu CY; Sheen YS; Jhuang JY; Tsai JH; Liau JY
Br J Ophthalmol; 2016 Feb; 100(2):274-7. PubMed ID: 26472403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
